Chroma Medicine Secures $135M In Series B Financing To Advance Breakthrough Epigenetic Editing Technology And Expand Pipeline Of Durable Precision Genomic Medicines
Amount Raised
$135 Million
Round Type
Series B
BostonBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion of a $135 million Series B financing led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. The financing will support advancement of Chroma's therapeutic programs toward the clinic, and continued investment in the company's core epigenetic editing platform.
Quick answer
Chroma Medicine raised $135 Million in a Series B round, dated March 1, 2023. Investors: T. Rowe Price, Wellington Management, Sofinnova Partners, Osage University Partners, Omega Funds, Newpath Partners, Janus Henderson Investors and Cormorant Asset Management. Chroma Medicine is based in Boston, Massachusetts, United States.
- How much did Chroma Medicine raise?
- Chroma Medicine raised $135 Million in a Series B round on March 1, 2023.
- Who invested in Chroma Medicine?
- T. Rowe Price, Wellington Management, Sofinnova Partners, Osage University Partners, Omega Funds, Newpath Partners, Janus Henderson Investors and Cormorant Asset Management are named as investors in this round.
- What does Chroma Medicine do?
- Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of disease.
- Where is Chroma Medicine based and how big is it?
- Chroma Medicine is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Chroma Medicine?
- Fundz holds 1 contact at Chroma Medicine. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Chroma Medicine that raised within 45 days of this round, from Fundz verified event records.
- GenoME Diagnostics raised $1.8M (Seed) on March 3, 2023.
- TransCode Therapeutics raised an undisclosed amount on April 14, 2023.
- Lapix Therapeutics raised $5.9M on April 14, 2023.
- OncoLize raised $1.7M (Seed) on April 13, 2023.
- DiaMedica Therapeutics raised $750K (Seed) on April 10, 2023.
- CTRL Therapeutics raised $10M (Seed) on April 10, 2023.
Who to call at Chroma Medicine, and when
A new round usually means Chroma Medicine is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Chroma Medicine raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Chroma Medicine, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Chroma Medicine. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Chroma Medicine raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansChroma Medicine raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.